Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TLX591 companion diagnostic - Telix Pharmaceuticals

Drug Profile

TLX591 companion diagnostic - Telix Pharmaceuticals

Alternative Names: 68Ga PSMA-11 - Telix Pharmaceuticals; 68Ga-HBED-CC-PSMA - Advanced Nuclear Medicine Ingredients; 68Ga-HBED-iPSMA PET; 68Ga-PSMA-11 - Advanced Nuclear Medicine Ingredients; 68Ga-PSMA-IRDye; 68Ga-PSMA-IRDye - Telix Pharmaceuticals; 68Ga PSMA-11 injection; Ga-68 gozetotide injection - Telix Pharmaceuticals; gallium-68 (68Ga) gozetotide injection - Telix Pharmaceuticals; Glu-urea-Lys(ahx)-hbed-CC; Illuccix; illumet; TLX 591CDx; TLX-591 companion diagnostic - Advanced Nuclear Medicine Ingredients/Telix Pharmaceuticals; TLX591-Cdx - Advanced Nuclear Medicine Ingredients/Telix Pharmaceuticals; TLX591-Sx; TLX591-Sx - Telix Pharmaceuticals

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advanced Nuclear Medicine Ingredients
  • Developer Emory University; Kanazawa University; Telix Pharmaceuticals
  • Class Antineoplastics; Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer
  • Phase I Breast cancer

Most Recent Events

  • 08 Nov 2023 WIIK Pharma and Telix Pharmaceuticals enter into a distribution agreement for the distribution of Illuccix® in the Nordic region
  • 20 Oct 2023 Telix Pharmaceuticals plans the commercial launch for TLX591 companion diagnostic for Renal cancer (Diagnosis) and Brain cancer (Diagnosis)
  • 18 Oct 2023 Telix Pharmaceuticals completes pre-NDA meeting with the Pharmaceuticals and Medical Devices Agency (PMDA) for a regulatory filling for Illuccix in Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top